Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGNAL: Insulin and Glucagon Action in the Liver
NCT07300982Phase 2Not yet recruiting
- Sponsor
- Duke University
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of glucagon in diabetes mellitus (DM) (2 arms), sponsored by Duke University. Primary endpoints: Glucose appearance at 90 minutes, Glucose disappearance at 90 minutes and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
glucagon
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07300982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300982.